Demographics, disease characteristics, laboratory and therapeutic data in patients with spondyloarthritis (SpA)
| Median (IQR 25%–75%) | Min | Max | |
| Age (years) | 36 (28–46) | 18 | 50 |
| Sex ratio | 2.35 | ||
| Marital status (%) | |||
| Unmarried | 55 | ||
| Married | 41 | ||
| Divorced | 4 | ||
| Educational attainment (%) | |||
| Primary education | 17 | ||
| Secondary education | 64 | ||
| University | 19 | ||
| Profession (%) | |||
| Unemployed | 17 | ||
| Student | 11 | ||
| Employed | 72 | ||
| Age of onset of SpA (years) | 20 (18–32) | 16 | 43 |
| Age at diagnostic (years) | 28 (22–35) | 16 | 46 |
| Disease duration (years) | 11 (5–16) | 1 | 32 |
| Type of SpA (%) | |||
| Axial | 58 | ||
| Axial and peripheral | 40 | ||
| Peripheral | 2 | ||
| Extra-articular manifestation | |||
| Uveitis | 9 | ||
| Nephropathy | 4 | ||
| Osteoporosis | 6 | ||
| BASMI | 1.5 (0–4) | 0 | 7 |
| PRO | |||
| Morning stiffness (min) | 5 (0–15) | 0 | 180 |
| PGA | 4 (3–6) | 0 | 9 |
| VAS axial pain | 5 (3–6) | 0 | 9 |
| VAS peripheral pain | 0 (0–0) | 0 | 7 |
| BAS-G | 50 (30–60) | 10 | 90 |
| MASES | 0 (0–0) | 0 | 4 |
| Number of tender joints | 0 (0–0) | 0 | 4 |
| Number of swollen joints | 0 (0–0) | 0 | 0 |
| BASDAI | 2,6 (1.8–3.8) | 0,2 | 6,5 |
| ASDAS-CRP | 2,18 (1.62-2.9) | 0.32 | 4,3 |
| BASFI | 3 (1.5–5.1) | 0,6 | 8,7 |
| Lequesne AFI of the right hip | 7 (5–8) | 4 | 16 |
| Lequesne AFI of the left hip | 8 (5–10) | 4 | 21 |
| NSAIDs, % | 91 | ||
| csDMARDs, % | 41 | ||
| TNF inhibitors, % | 38 |
AFI, Algo-Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BAS-G, Bath Ankylosing Spondylitis Global Score; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; csDMARDS, conventional synthetic disease-modifying antirheumatic drugs; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; Max, maximum; Min, minimum; NSAIDs, non-steroidal anti-inflammatory drugs; PGA, patient global assessment; PRO, patient-reported outcomes; TNF, tumour necrosis factor; VAS, Visual Analogue Scale.